Kailera Therapeutics, Inc.
BioSniper AI · KLRA
Kailera Therapeutics is an advanced clinical-stage biotechnology company developing oral GLP-1 therapies for obesity and diabetes, having reported positive Phase 3 results alongside gastrointestinal side effects.
Key risk: GI side effects in Phase 3
Spotter reads the filings and answers with citations.
BioSniper Score
Based on 4 of 6 signals
Tracking 3 pipeline candidates for Kailera Therapeutics, Inc. · Updated within the last hour.
Kailera Therapeutics is an advanced clinical-stage biotechnology company developing oral GLP-1 therapies for obesity and diabetes, having reported positive Phase 3 results alongside gastrointestinal side effects.
- Kailera is an advanced clinical-stage biotechnology company focused on obesity and diabetes [news 2026-07-07].
- Its oral GLP-1 met Phase 3 targets, but reported GI side effects led to a 9% stock drop [news 2026-07-07].
- The company is collaborating with Hengrui Pharma and will present two abstracts at the ADA Scientific Sessions [news 2026-05-13].
- Insiders, including Bain Capital and executives, made significant stock purchases and awards at $16.00 per share in April 2026 [insider_transaction].
What works
- Positive Phase 3 results for its oral GLP-1 candidate in obesity and diabetes [news 2026-07-07].
- Strong insider buying and stock awards at $16.00 per share in April 2026, indicating confidence from major investors and management [insider_transaction].
- Collaboration with Hengrui Pharma, a global pharmaceutical company, to advance development [news 2026-05-13].
What to weigh
- Gastrointestinal side effects reported in the Phase 3 trial, causing a 9% stock decline [news 2026-07-07].
- Post-IPO stock volatility observed in April 2026 [news 2026-04-20].
- Clinical-stage company with no approved products and no disclosed financial runway metrics.
From the filings
Quoted directly from source documents.
Phase 3 clinical results and stock reaction
“Kailera Therapeutics oral GLP-1 meets Phase 3 targets for obesity and diabetes. KLRA stock falls 9% on reported GI side effects.”
News · July 7, 2026
Upcoming abstract presentation at ADA
“Hengrui and Kailera to present two abstracts at ADA Scientific Sessions.”
News · May 13, 2026
Risks & what to watch (3)›
Key risks
- GI side effects in Phase 3 — Reported gastrointestinal side effects may affect regulatory approval and market acceptance [news 2026-07-07].
- Clinical-stage development risk — No approved products; further trials and regulatory reviews are required [news 2026-07-07].
- Competitive obesity drug market — Multiple GLP-1 and other obesity therapies are in development or approved, creating competitive pressure [news 2026-07-07].
What to watch
- Presentation of two abstracts at the ADA Scientific Sessions, which may provide additional data on efficacy and safety [news 2026-05-13].
- Further disclosure of detailed Phase 3 results and regulatory discussions regarding the GI side effect profile [news 2026-07-07].
- Insider trading activities post-IPO, as they may signal management's view on near-term prospects [insider_transaction].
Sources: Insider filings · News · Generated July 14, 2026 · How we verify sources →
Unlock the full Kailera Therapeutics, Inc. dossier
Sign in free to see catalysts, full pipeline, financials, FDA decisions, news, and run live AI deep-dives.
Free account includes:
- Full pipeline, catalysts, financials & FDA decisions for Kailera Therapeutics, Inc.
- 200 free AI credits / month to run live Spotter deep-dives
- Watchlist, news alerts & the biotech event calendar
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
22.1 months
OCF -$68M · Net income -$79M
No tracked pipeline phase
3 candidates
No upcoming catalysts tracked
5 buys · 0 sells (180d)
Runway
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Kailera Therapeutics, Inc.?
Kailera Therapeutics is an advanced clinical-stage biotechnology company developing oral GLP-1 therapies for obesity and diabetes, having reported positive Phase 3 results alongside gastrointestinal side effects.
Who is the CEO of Kailera Therapeutics, Inc.?
Mr. Ronald C. Renaud Jr., M.B.A. is the chief executive officer of Kailera Therapeutics, Inc. (KLRA).
Where is Kailera Therapeutics, Inc. headquartered?
Kailera Therapeutics, Inc. (KLRA) is headquartered in Waltham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on Kailera Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.